Search Results for "covid"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for covid. Results 31 to 40 of 93 total matches.
FDA Authorizes Moderna COVID-19 Vaccine
The Medical Letter on Drugs and Therapeutics • Jan 25, 2021 (Issue 1616)
FDA Authorizes Moderna COVID-19 Vaccine ...
On December 18, 2020, the FDA issued an Emergency
Use Authorization (EUA) for the Moderna mRNA-based
vaccine for prevention of COVID-19 in persons
≥18 years old. The Pfizer-BioNTech mRNA-based
vaccine received an FDA EUA for the same indication
in persons ≥16 years old on December 11, 2020.
COVID-19 Update: Bebtelovimab EUA Withdrawn (online only)
The Medical Letter on Drugs and Therapeutics • Dec 26, 2022 (Issue 1666)
COVID-19 Update: Bebtelovimab EUA Withdrawn (online only) ...
The FDA has withdrawn its Emergency Use
Authorization (EUA) of the investigational anti-SARS-CoV-2 monoclonal antibody bebtelovimab
(LY-CoV1404 – Lilly) for treatment of COVID-19.
Bebtelovimab is not expected to retain activity
against the Omicron variants BQ.1 and BQ.1.1, which
currently cause the majority of COVID-19 cases in all
regions of the US.
Table: Over the Counter At-Home Tests for COVID-19 (online only)
The Medical Letter on Drugs and Therapeutics • Oct 20, 2021 (Issue 5041)
Table: Over the Counter At-Home Tests for COVID-19 (online only) ...
View the Table: Over the Counter At-Home Tests for COVID-19
Med Lett Drugs Ther. 2021 Oct 20;63(5041):e1 doi:10.58347/tml.2021.5041a | Show Introduction Hide Introduction
Bamlanivimab and Etesevimab for Post-Exposure Prophylaxis of COVID-19
The Medical Letter on Drugs and Therapeutics • Oct 18, 2021 (Issue 1635)
Bamlanivimab and Etesevimab for Post-Exposure Prophylaxis of COVID-19 ...
In February 2021, the FDA issued an Emergency Use
Authorization (EUA) for the investigational monoclonal
antibodies bamlanivimab and etesevimab (Lilly) for
use together to treat mild to moderate COVID-19
in persons ≥12 years old who weigh ≥40 kg and
are at high risk of progression to severe disease or
hospitalization. The FDA has now expanded this
EUA to allow use of the antibodies together for post-exposure
prophylaxis of COVID-19 in such persons
if they are not fully vaccinated against COVID-19 or
are unlikely to have an adequate immune response
to full vaccination and have...
In Brief: Pfizer/BioNTech COVID-19 Vaccine Authorized for Children 5-11 Years Old
The Medical Letter on Drugs and Therapeutics • Nov 29, 2021 (Issue 1638)
In Brief: Pfizer/BioNTech COVID-19 Vaccine Authorized for Children 5-11 Years Old ...
The FDA has issued an Emergency Use Authorization
(EUA) for a lower-strength (10 mcg/0.2 mL) formulation
of the mRNA-based COVID-19 vaccine
manufactured by Pfizer/BioNTech (Comirnaty) for use
in children 5-11 years old. The original formulation
of (Comirnaty) (30 mcg/0.3 mL) is FDA-licensed for
use in persons ≥16 years old and available under an
EUA for use in adolescents 12-15 years old.
An EUA for Anakinra (Kineret) for COVID-19 (online only)
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022 (Issue 1665)
An EUA for Anakinra (Kineret) for COVID-19 (online only) ...
The recombinant interleukin-1 (IL-1) receptor
antagonist anakinra (Kineret – Sobi) has been
granted an FDA Emergency Use Authorization
(EUA) for treatment of hospitalized adults with
confirmed COVID-19 pneumonia who require low- or
high-flow supplemental oxygen, are at risk of
progressing to severe respiratory failure, and are
likely to have elevated plasma levels of soluble
urokinase plasminogen activator receptor (suPAR).
Anakinra has been available in the US for years; it
is FDA-approved for multiple indications, including
rheumatoid arthritis. Assays for suPAR are...
COVID-19 Update: NIH Recommends Against Ivermectin
The Medical Letter on Drugs and Therapeutics • Jun 13, 2022 (Issue 1652)
COVID-19 Update: NIH Recommends Against Ivermectin ...
On April 29, the NIH recommended against use of the antiparasitic drug ivermectin for treatment of COVID-19 outside of a clinical trial. The recommendation was made because recent randomized, placebo-controlled trials of ivermectin have produced negative results and because alternative drugs that have been shown to be effective for treatment of COVID-19 are available.
Booster Dose of the Pfizer/BioNTech COVID-19 Vaccine (Comirnaty)
The Medical Letter on Drugs and Therapeutics • Oct 18, 2021 (Issue 1635)
Booster Dose of the Pfizer/BioNTech COVID-19 Vaccine (Comirnaty) ...
On September 22, on the advice of its Vaccines and
Related Biologic Products Advisory Committee, the
FDA expanded the Emergency Use Authorization
(EUA) for the Pfizer/BioNTech mRNA-based COVID-19
vaccine (Comirnaty) to include administration of a
booster dose ≥6 months after a 2-dose primary series
in adults who are ≥65 years old or at high risk for severe
COVID-19 because of an underlying medical condition
or frequent institutional or occupational exposure
to SARS-CoV-2 (see Table 1). The FDA Advisory
Committee recommended against authorization of a
booster dose of Comirnaty...
In Brief: Guillain-Barré Syndrome with the Johnson & Johnson COVID-19 Vaccine
The Medical Letter on Drugs and Therapeutics • Aug 09, 2021 (Issue 1630)
In Brief: Guillain-Barré Syndrome with the Johnson & Johnson COVID-19 Vaccine ...
On July 12, 2021, the FDA added a warning to the
Fact Sheet for the Johnson & Johnson (Janssen)
adenovirus-based COVID-19 vaccine about an
increased risk of Guillain-Barré syndrome (GBS)
following administration of the product.
COVID-19 Update: New Novavax Vaccine Formulation for 2023-2024
The Medical Letter on Drugs and Therapeutics • Nov 13, 2023 (Issue 1689)
COVID-19 Update: New Novavax Vaccine Formulation for 2023-2024 ...
A new 2023-2024 formulation of the adjuvanted
protein subunit COVID-19 vaccine manufactured by
Novavax that was developed to more closely target
currently circulating SARS-CoV-2 variants has been
made available in the US under an FDA Emergency Use Authorization (EUA) for use in persons ≥12
years old. The original formulation of the Novavax
vaccine is no longer authorized for use in the US.
In September, updated formulations of the mRNA
COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) were
licensed by the FDA for use in persons ≥12 years old
and...
Med Lett Drugs Ther. 2023 Nov 13;65(1689):182-3 doi:10.58347/tml.2023.1689b | Show Introduction Hide Introduction